Skip to main content
OpenTrials
Completed

NCT Number: NCT06285214

Study of V117957 in Interstitial Cystitis/Bladder Pain Syndrome

The purpose of this study is to evaluate the safety, tolerability and efficacy of V117957 in subjects with interstitial cystitis/bladder pain syndrome, compared to placebo.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

Female

Study type

Interventional

Phase

Phase 1

Primary location

Urology Centers of Alabama, PC, Homewood, Alabama, United States

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Key Inclusion Criteria include:

  • Female, age ≥18 years and capable of voiding independently. Able to comply with acceptable methods of contraception.
  • Diagnosis of IC/BPS or meets criteria for IC/BPS as defined by the American Urology Association as "an unpleasant sensation (pain, pressure, discomfort) perceived to be related to the urinary bladder, associated with lower urinary tract symptoms for more than six weeks duration, in the absence of infection or other identifiable causes".
  • Subject has Bladder Pain/Interstitial Cystitis Symptom Scale (BPIC-SS) total score of ≥19 and worst bladder pain/discomfort sub-score of ≥4 to ≤9.
  • Has undergone evaluation to rule out other conditions that cause bladder pain/discomfort. Any microscopic or gross hematuria that has not been evaluated in the past 12 months will require appropriate clinical evaluation to determine study eligibility.

Key Exclusion Criteria include:

  • Pelvic floor tenderness in the absence of bladder tenderness on physical examination by primary investigator.
  • Urinary tract infection (UTI) within the past 30 days, or history of recurrent UTI.
  • Hematuria determined to be associated with bladder malignancy or other significant pathology.
  • Had surgical procedure at any time that affected bladder function.
  • Received intravesical therapy or had bladder hydrodistension, fulguration, botulinum toxin, or triamcinolone bladder injection, percutaneous nerve stimulation. A subject receiving such treatment(s) prior to screening is eligible if in the opinion of the investigator the procedure/ treatment resulted in no notable or enduring effect and subject continues to exhibit stable symptomology.
  • Has current or history of clinically significant kidney disease or abnormal kidney function, or nephrolithiasis.

Other protocol-specific inclusion and exclusion criteria may apply.

Treatment and study plan

V117957

Drug

V117957 1 mg - 1 tablet taken orally at bedtime.

Placebo

Drug

Placebo to match V117957 tablets - 1 tablet taken orally at bedtime.

Primary outcomes

  1. Change From Baseline for Worst Bladder Pain/Discomfort Scores Overnight / Over-the-day

    Time frame: Assessed at Baseline, Weeks 2 and 8. Change from Baseline to Week 2 (Period 1) and Week 8 (Period 2) reported.

    Each evening and morning the subject responded to the question "Please indicate the worst bladder pain/discomfort you have had overnight/over-the-day" using an 11-point numerical rating scale (NRS) that ranges from 0 = "no bladder pain/discomfort" to 10 = "as bad as you can imagine bladder pain/discomfort."

Sponsors and collaborators

Lead sponsor

Imbrium Therapeutics

Industry

Collaborators

  • Purdue Pharma LP

Registry information

Official study title

Multicenter, Randomized, Double-blind Placebo-controlled, Crossover Study to Investigate Effects of V117957 in Female Subjects With Interstitial Cystitis/Bladder Pain Syndrome

Important dates

Study start
2022
Primary completion
2025
Study completion
2025
First posted
Feb 29, 2024
Registry last updated
Mar 9, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.